Entrectinib

Last Updated: 06/30/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 569 publications

Mechanistic PBPK Modeling of pH-Modifying Excipient Effects to Guide Formulation Design for Mitigating pH-Mediated DDIs.

Mechanistic PBPK Modeling of pH-Modifying Excipient Effects to Guide Formulation Design for Mitigating pH-Mediated DDIs.

Journal: Molecular pharmaceutics
Published: June 16, 2026

Differences Among Genomic Profiling Tests for Bone and Soft-Tissue Sarcomas in a Universal Health Insurance System.

Differences Among Genomic Profiling Tests for Bone and Soft-Tissue Sarcomas in a Universal Health Insurance System.

Journal: The Journal of bone and joint surgery. American volume
Published: May 27, 2026

Secretory Breast Carcinoma in A Six-Year-Old Girl: Case Report With Genetic Insights and Therapeutic Implications.

Secretory Breast Carcinoma in A Six-Year-Old Girl: Case Report With Genetic Insights and Therapeutic Implications.

Journal: Balkan journal of medical genetics : BJMG
Published: May 18, 2026

Switching Tracks: Activity of Entrectinib After Progression While on Larotrectinib in Neurotrophin Receptor Tyrosine Kinase-Fused Pediatric High-Grade CNS Tumors.

Switching Tracks: Activity of Entrectinib After Progression While on Larotrectinib in Neurotrophin Receptor Tyrosine Kinase-Fused Pediatric High-Grade CNS Tumors.

Journal: JCO precision oncology
Published: May 14, 2026

TRK inhibitors in pediatric gliomas.

TRK inhibitors in pediatric gliomas.

Journal: Neuro-oncology advances
Published: April 30, 2026

Fibroblasts neurotrophin signaling sustains pathological vascular maturation in rheumatoid arthritis.

Fibroblasts neurotrophin signaling sustains pathological vascular maturation in rheumatoid arthritis.

Journal: bioRxiv : the preprint server for biology
Published: April 10, 2026

Targeting wild type NTRK decreases brain metastases of lung cancers non-driven by NTRK fusions.

Targeting wild type NTRK decreases brain metastases of lung cancers non-driven by NTRK fusions.

Journal: bioRxiv : the preprint server for biology
Published: March 27, 2026

Glioblastoma, IDH-wildtype, with a novel MEF2D-NTRK1 gene fusion: a case report.

Glioblastoma, IDH-wildtype, with a novel MEF2D-NTRK1 gene fusion: a case report.

Journal: Frontiers in oncology
Published: March 18, 2026

Repurposing ALK Inhibitors as Influenza and Corona Virus Antivirals Targeting Lymphocyte Tyrosine Kinase (LTK).

Repurposing ALK Inhibitors as Influenza and Corona Virus Antivirals Targeting Lymphocyte Tyrosine Kinase (LTK).

Journal: Virus research
Published: March 13, 2026

STRN::NTRK3-fused neoplasm with "monster cells" in the pelvis of a young adult female: expanding the clinicopathologic spectrum of NTRK-rearranged neoplasms.

STRN::NTRK3-fused neoplasm with "monster cells" in the pelvis of a young adult female: expanding the clinicopathologic spectrum of NTRK-rearranged neoplasms.

Journal: Virchows Archiv : an international journal of pathology
Published: March 11, 2026

Case Report: Dynamic TKI combination strategies for EGFR-mutant NSCLC with acquired ROS1 fusion and brain metastases.

Case Report: Dynamic TKI combination strategies for EGFR-mutant NSCLC with acquired ROS1 fusion and brain metastases.

Journal: Frontiers in oncology
Published: March 08, 2026

Discovery of a Novel Phenyl Thiophene-3-carboxamide Derivative DZX19 as an Orally TRK Inhibitor with Potent Antitumor Effects.

Discovery of a Novel Phenyl Thiophene-3-carboxamide Derivative DZX19 as an Orally TRK Inhibitor with Potent Antitumor Effects.

Journal: Journal of medicinal chemistry
Published: February 25, 2026
Showing 1-12 of 569

Last Updated: 06/30/2026